Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:DiVA.org:uu-83237" > Evaluation of anaem...

1 av 1
Föregående post
Nästa post
Till träfflistan

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		03245naa a2200373 4500
001		oai:DiVA.org:uu-83237
003		SwePub
008		061025s2006 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-832372 URI
024	7	a https://doi.org/10.1111/j.1600-0609.2006.00739.x2 DOI
040		a (SwePub)uu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Birgegård, Gunnar,d 1944-u Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi4 aut
245	1 0	a Evaluation of anaemia in patients with multiple myeloma and lymphoma :b findings of the European Cancer Anaemia Survey
264	1	b Wiley,c 2006
338		a print2 rdacarrier
520		a OBJECTIVES: Until recently, no prospective epidemiologic survey of lymphoma and multiple myeloma (L/MM) in European cancer patients had been conducted; furthermore, data on prevalence, incidence, and treatment patterns of L/MM were limited or unavailable. Here we define anemia prevalence, incidence, and treatment patterns, and identify anemia risk factors in European L/MM patients. METHODS: Data for a subgroup of 2360 L/MM patients in the European Cancer Anaemia Survey (ECAS) were analyzed; variables included age, gender, tumor type/stage, cancer and anemia treatment, WHO performance status, and hemoglobin (Hb) levels. RESULTS: 2316 patients were evaluable (1612 L and 704 MM). Anemia rate at enrollment was 52.5%. At enrollment, Hb levels correlated significantly with WHO scores (r = -0.306, P < 0.001). Anemia prevalence during ECAS was 72.9% (MM, 85.3%; non-Hodgkin's lymphoma, 77.9%; Hodgkin's disease, 57.4%); incidence in chemotherapy patients was 55.4%. Only 47.3% of patients anemic any time during ECAS received anemia treatment; overall Hb nadir for initiating treatment was 8.9 g/dL (epoetin, 9.5 g/dL; transfusion, 8.2 g/dL). Factors found to significantly (P < 0.03) increase anemia risk were low initial Hb, female gender, persistent/resistant disease, and platinum chemotherapy. CONCLUSIONS: L/MM patients have a high prevalence and incidence of anemia; however, anemia is not optimally treated. Anemia is common in L/MM patients and, given its known adverse impact on physical functioning and quality-of-life variables including fatigue and cognitive function, anemia management should be an integral part of their care. Predictive factors identified by ECAS may help clinicians develop optimal anemia treatment strategies for L/MM patients.
653		a European cancer anaemia survey
653		a anaemia
653		a epoetin alpha
653		a lymphoma
653		a multiple myeloma
653		a MEDICINE
653		a MEDICIN
700	1	a Gascón, Pere4 aut
700	1	a Ludwig, Heinz4 aut
710	2	a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
773	0	t European Journal of Haematologyd : Wileyg 77:5, s. 378-386q 77:5<378-386x 0902-4441x 1600-0609
856	4	u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1600-0609.2006.00739.x
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-83237
856	4 8	u https://doi.org/10.1111/j.1600-0609.2006.00739.x

Hitta via bibliotek

European Journal of Haematology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Birgegård, Gunna ...; Gascón, Pere; Ludwig, Heinz

Artiklar i publikationen: European Journal ...

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se